Benefit-Risk SIG

The Benefit-Risk SIG was set up at the start of 2012 to help support those involved in this fast evolving area.

The main aims of the SIG are:

• To understand how best to apply Benefit-Risk Methodologies across the Pharmaceutical Industry
• To discuss and make recommendations on key methodological issues
• To share examples of how Benefit-Risk has been used within pharmaceutical companies
• To share external information including new developments around Benefit-Risk

Currently the SIG has subgroups working on:
 
• Literature review
• Points to consider for creating effects tables
• MCDA/SMAA
• Benefit-Risk in the HTA setting (together with the HTA SIG)
• Training
• Bayesian applications in Benefit-Risk
• Benefit-Risk BLOG

If you have an interest in being involved in this SIG or have an interesting case study or experience of carrying out a structured Benefit-Risk assessment to share, please contact Alexander Schacht

email: Schacht_alexander@lilly.com

Our BLOG can be found under www.benefit-risk-assessment.com

Latest News


Show all news
abbott

Medical Statistician

read more...

AZ_RGB_512x196px

Clinical Trial Design Methodology Expert – Statistical Innovation Team

read more...

Chiltern Logo Horz_TaglineRegistered_Screen

Biostatistician / Senior Biostatistician

read more...